To study the effect of oral magnesium supplementation on Blood pressure and lipid profile in patients during initial stage of hypertension

To study the effect of oral magnesium supplementation on Blood pressure and lipid profile in prehypertensive patients: A prospective randomised controlled study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056417

Enrollment

100

Registered

2023-08-11

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I119- Hypertensive heart disease withoutheart failure

Interventions

Intervention1: Magnesium supplementation: magnesium supplementation 550mg Once daily after breakfast will be given orally for 12 weeks Control Intervention1: Healthy individuals: We are not going to

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals not consuming any antihypertensive medicine. 2. Individuals having systolic blood pressure of 120-139mmHg and diastolic blood pressure of 80-89mmHg. 3. Ability to meet follow up requirements for minimum of 12 weeks. 4. Patients who are willing to get enrolled in study.

Exclusion criteria

Exclusion criteria: 1. Age should be less than 18 yrs and more than 60 yrs. 2. Chronic disease â?? Chronic Kidney Disease, Diabetes Mellitis, Coronary Artery Disease and Acute Liver Disease. 3. Using any supplementation (multivitamins, Herbals medicine) within 6 months. 4. Patients with any acute illness affecting hemodynamics like sepsis, fever, acute febrile illness etc. 5. History of malignancy. 6. History drug and alcohol abuse. 7. Secondary Hypertension. 8. Pregnant and lactating women. 9. Patient unable to attend follow up. 10. Patient who is refusing for enrolment into study.

Design outcomes

Primary

Measure	Time frame
To determine effects of oral magnesium supplementation on blood pressure in prehypertensive patients.Timepoint: 3 months	—

Secondary

Measure	Time frame
To determine the effects of oral magnesium supplementation on lipid profile in prehypertensive patients.Timepoint: 3 months	—

Countries

India

Contacts

Public ContactJasmeen

Government medical college, Patiala

drneetusharma1975@gmail.com9417075783

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026